HitGen Inc. A (688222 SHG) stock market data APIs

¥11.55 -0.65(-5.3%)
as of January 14, 2025

HitGen Inc. A Financial Data Overview

Price chart is built with Anychart

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGT01 and HGT02, an tumor immunology for cancer. In addition, it offers HGT03, a protein degrader, and HGT04, a transcriptomics for cancer; and HGT05, a kinase inhibitor for liver cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation, and HGC245, a kinase inhibitor for glaucoma. The company's nucleic acid drug pipeline includes HGP2142, an TGF-ß1 specific siRNA drug for liver cancer; HGN001, a nucleic acid drug for specific mutation of cancer target; and HGN002 for Solid tumor. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.

Prev. Close 12.2
Open 11.55
Volume 5 112 K
High 12.2
Low 11.43
52 wk Range 8.35-16.49
Market Cap 4 888 M
P/E Ratio 93.8462
Shares Outstanding 401 M
Revenue 424 M
EPS 0.0371
Dividends (Yield) 0.0043
Beta 0.156

Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get HitGen Inc. A data using free add-ons & libraries


Get HitGen Inc. A Fundamental Data

HitGen Inc. A Fundamental data includes:

  • Net Revenue: 424 M
  • EBITDA: 79 218 K
  • Earnings Per Share: 0
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get HitGen Inc. A Earnings data

Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2023-04-28
  • EPS/Forecast: NaN
GET THE PACKAGE

Get HitGen Inc. A End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
  • Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Chat